Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an italian expert panel

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 684-697

  Pession, Andrea ^a   Masetti, Riccardo ^b   Gaidano, Gianluca ^c   Tosi, Patrizia ^d   Rosti, Giovanni ^e   Aglietta, Massimo ^f   Specchia, Giorgina ^g   Porta, Fulvio ^h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Ospedale Civile Infermi   (Italy)

^d OSPEDALE CA FONCELLO   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Allopurinol; Expert panel; Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; BICARBONATE; DIURETIC AGENT; FLUDARABINE; PEGLOTICASE; RASBURICASE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ALGORITHM; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FLUID THERAPY; HIGH RISK POPULATION; HUMAN; HYPERURICEMIA; INJECTION SITE INDURATION; ITALY; KIDNEY FUNCTION TEST; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDLINE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PEER REVIEW; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TUMOR LYSIS SYNDROME; URTICARIA; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; ITALY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 82455187894     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0041-1     Document Type: Article

References (32)

1. Loftus EV Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review. Aliment Pharmacol Ther. 2002;16:51-60. (Pubitemid 34123864)
2. Kappelman MD, Rifas-Shiman SL, Porter C., et al.Direct health care costs of Crohn's disease andulcerative colitis in United States children andadults. Gastroenterology. 2008;135:1907-1913.
3. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J.The costs of Crohn's disease in the United Statesand other Western countries: A systematic review.Curr Med Res Opin. 2008;24:319-328. (Pubitemid 351294380)
4. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000;95:524-530. (Pubitemid 30106188)
5. Blomqvist P, Ekbom A. Inflammatory boweldisease: Health care and costs in Sweden in 1994.Scand J Gastroenterol. 1997;32:1134-1139. (Pubitemid 27523846)
6. Bernstein CN, Papineau N, Zajaczkowski J,Rawsthorne P, Okrusko G, Blanchard JF. Directhospital costs for patients with inflammatorybowel disease in a Canadian tertiary care universityhospital. Am J Gastreoenterol. 2000;95:677-683. (Pubitemid 30123901)
7. Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates forinflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis.2007;13:1529-1535.
8. Bassi A, Dodd S, Williamson P, Bodger K. Cost-of-illness of inflammatory bowel disease in the UnitedKingdom: A single centre retrospective study. Gut.2004;53:1471-1478. (Pubitemid 39265268)
9. Prescribing Information. REMICADE (infliximab).Malvern, PA: Centocor Ortho Biotech, Inc.;November 2009.
10. Targan SR, Hanauer SB, van Deventer SJ.H., et al. Ashort-term study of chimeric monoclonal antibodycA2 to tumor necrosis factor alpha for Crohn'sdisease. N Engl J Med. 1997;337:1029-1035.
11. Hanauer SB, Feagan BG, Lichtenstein G.R., et al.Maintenance infliximab for Crohn's disease:The ACCENT I randomized trial. Lancet.2002:359:1541-1549. (Pubitemid 34621118)
12. Sands BE, Anderson FH, Bernstein C.N., et al.Infliximab maintenance therapy for fistulizingCrohn's disease. N Engl J Med. 2004;350:876-885. (Pubitemid 38252535)
13. Present DH, Rutgeerts P, Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405. (Pubitemid 29205403)
14. Rutgeerts P, Van Assche G, Vermeire S. Optimizinganti-TNF treatment in inflammatory bowel disease.Gastroenterology. 2004;126:1593-1610. (Pubitemid 38649876)
15. Colombel JF, Rutgeerts P, Yan S., et al. Infliximab(Remicade) maintenance treatment results in lowerhospitalization rate in Crohn's disease patients.Gastroenterology. 2002;122(Suppl. 4):W1344.
16. Williams JB, Cross RK, Thameen D., et al. Long-term infliximab maintenance infusion regimensand rates of hospitalization, surgery and disabilityin Crohn's disease patients. Gastroenterology.2005;128(Suppl. 2):AW1076.
17. Williams JB, Weber LR, Beaulieu D.B., et al. Long-term infliximab maintenance infusion regimensand rates of hospitalization, surgery, anddisability in Crohn's disease. Gastroenterology.2006;130(Suppl. 2):A-143.
18. Schnitzler F, Fidder H, Ferrante M., et al. Long-term outcome of treatment with infliximab in 614patients with Crohn's disease: Results from a single-centre cohort. Gut. 2009;58:492-500.
19. Stein DJ, Ananthakrishnan AN, Issa M., et al.Impact of prior irregular infliximab dosing onperformance of long-term infliximab maintenancetherapy in Crohn's disease. Inflamm Bowel Dis.2010;16:1173-1179.
20. Lichtenstein GR, Yan S, Bala M, Blank M, SandsBE. Infliximab maintenance treatment reduceshospitalizations, surgeries, and procedures infistulizing Crohn's disease. Gastroenterology.2005;128:862-869. (Pubitemid 40523539)
21. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156. (Pubitemid 34815854)
22. Bokemeyer B, Teml A, Roggel C., et al. Adherence tothiopurine treatment in out-patients with Crohn'sdisease. Aliment Pharmacol Ther. 2007;26:217-225. (Pubitemid 46985496)
23. Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S,Raptis N, Kalantzis N. How adherent to treatment withazathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis. 2007;13:446-450. (Pubitemid 46668250)
24. Shaya FT, El Khoury AC, Wong W., et al. Persistence with pharmacotherapy for gastrointestinal disease:associated costs of health care. P T. 2006;31:657-665. (Pubitemid 44851974)
25. Higgins PD, Rubin DT, Kaulback K, SchoenfieldPS, Kane SV. Systematic review: Impact of non-adherence to 5-aminosalicylic acid products onthe frequency and cost of ulcerative colitis flares.Aliment Pharmacol Ther. 2009;29:247-257.
26. Kane S, Shaya F. Medication non-adherence isassociated with increased medical health carecosts. Dig Dis Sci. 2008;53:1020-1024. (Pubitemid 351379831)
27. Kane S, Dixon L. Adherence rates with infliximabtherapy in Crohn's disease. Aliment PharmacolTher. 2006;24:1099-1103. (Pubitemid 44386535)
28. Kane SV, Chao J, Mulani PM. Adherence toinfliximab maintenance therapy and health careutilization and costs by Crohn's disease patients.Adv Ther. 2009;26:1-11.
29. PharMetrics, Inc. LifeLink Health Plan ClaimsDatabase. Watertown, MA: IMS Health; 2010.
30. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterol. 2000;95:1955-1960.
31. Cramer JA, Roy A, Burrell A., et al. Medicationcompliance and persistence: Terminology anddefinitions. Value Health. 2008;11:44-47.
32. Jackson CA, Clatworthy J, Robinson A, Horne R. Factorsassociated with non-adherence to oral medication forinflammatory bowel disease: A systematic review. Am J Gastroenterol. 2010;105:525-539.